Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of cancer. The company operates within the diagnostic testing, biotechnology, and precision oncology industries, with a core emphasis on screening and early-stage cancer detection using non-invasive and minimally invasive technologies. Its business is primarily driven by the development, commercialization, and reimbursement of proprietary cancer screening and diagnostic tests.
The company’s flagship product, Cologuard, is a noninvasive, stool-based DNA test for colorectal cancer screening, which represents the largest revenue driver. Additional products and pipelines extend into blood-based cancer screening, oncoguard tests, and tumor profiling. Exact Sciences primarily serves healthcare providers, clinical laboratories, health systems, and payors, with patients as end users. Founded in 1995, the company initially focused on colorectal cancer detection and significantly expanded following regulatory approvals and reimbursement milestones in the 2010s, evolving into a broader oncology diagnostics platform.
Business Operations
Exact Sciences operates through two primary business segments: Screening and Precision Oncology. The Screening segment includes colorectal and other cancer screening tests, most notably Cologuard and Cologuard Plus, and accounts for the majority of company revenue. Revenue is generated through test volume reimbursed by government and private payors, particularly Medicare. The Precision Oncology segment includes molecular tumor profiling and therapy selection tools such as Oncoguard, Oncoguard-Liver, and Oncoguard-Pancreas, as well as earlier-generation tests like Oncoguard-Cancer.
The company conducts most of its testing through centralized laboratories in the United States and owns proprietary sample-processing technologies, biomarker panels, and bioinformatics platforms. International operations are more limited but include commercial partnerships and licensing arrangements. Exact Sciences has historically expanded capabilities through acquisitions, including Genomic Health, which added genomic tumor profiling expertise and laboratory infrastructure to its oncology portfolio.
Strategic Position & Investments
Exact Sciences’ strategy centers on expanding its cancer detection platform beyond colorectal cancer into multi-cancer and blood-based screening while increasing adoption through clinical evidence, guideline inclusion, and expanded reimbursement. Growth initiatives focus on next-generation screening tests, broader population coverage, and earlier detection across multiple cancer types. The company continues to invest heavily in research and development to support clinical trials, regulatory submissions, and pipeline expansion.
Key strategic investments include the acquisition of Genomic Health, which strengthened the company’s precision oncology and recurrence risk testing capabilities, and ongoing internal development of blood-based screening technologies. Exact Sciences positions itself as a leader in noninvasive cancer screening, leveraging large-scale clinical datasets, proprietary biomarkers, and established relationships with payors and healthcare providers to create barriers to entry.
Geographic Footprint
Exact Sciences is headquartered in Madison, Wisconsin, with primary operations and laboratories in the United States. The company’s commercial footprint is predominantly domestic, reflecting the U.S.-centric nature of colorectal cancer screening reimbursement and regulatory frameworks. Most revenue is generated from U.S. payors, including Medicare and large private insurers.
Internationally, Exact Sciences has a limited but growing presence through partnerships, licensing agreements, and select commercialization efforts in Europe and other developed markets. While international operations currently represent a small portion of revenue, the company views global expansion as a long-term opportunity as regulatory pathways and reimbursement environments mature.
Leadership & Governance
Exact Sciences is led by an executive team with backgrounds in diagnostics, life sciences, and healthcare commercialization. The company emphasizes a strategy driven by scientific validation, clinical outcomes, and broad access through reimbursement and guideline inclusion. Governance practices align with public company standards and are overseen by an independent board of directors.
Key executives include:
- Kevin T. Conroy – Chairman and Chief Executive Officer
- Aaron J. Krause – Chief Financial Officer
- Katherine S. Andreas – Executive Vice President and Chief Commercial Officer
- Sean McGuire – Executive Vice President and Chief Scientific Officer
- Brian Baranick – Executive Vice President and General Counsel
The leadership team’s strategic vision centers on transforming cancer detection through earlier, more accessible testing while maintaining rigorous clinical and regulatory standards.